Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.

Officials had initially linked 97 cases to a single conference held by Biogen in February in Boston, but a new study tracking viral genomes suggests the number may be as high as 20,000.

In a small trial of deceased volunteers, a Seattle-based company called Recompose demonstrates that its method for “natural organic reduction” of a human body completely breaks down soft tissue.

Federal grant support for technology transfer at universities will strengthen the national innovation system.

The state’s Environmental Protection Agency says that evidence of the chemical’s link to neurological problems in children is overwhelming.

A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.

A new study suggests that sponsors downplay their influence when reporting trials carried out in collaboration with academic researchers.

Almost half of all patents relating to the genes of marine organisms belong to one large international corporation, BASF, a new study reveals.  

In efforts to translate basic-science results into pharmaceuticals and other technologies, success cannot be taken for granted.

Small trials using younger donors and elderly recipients hint that mesenchymal stem cell transfers might reduce frailty. 

The editorial board at the International Journal of Occupational and Environmental Health accuses its publisher of promoting corporate interests.

Industry professionals make more than academic researchers, but for professors, it may not be about the money.

Graduate students from The Scripps Research Institute share how they prepared to enter policy, law, biotech, and beyond.

The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.

Heads of academia and industry mingled with the vice president and the secretary of Health and Human Services at a biotech summit.

The proposed changes follow revelations in recent years that committee members preparing reports for the Academies did not disclose industry relationships. 

A report finds that new medications still take about 12 years to go from patent to patient.

Researchers and institutions seek to bridge the gap between emerging life science professionals and available positions.